Merck and Pfizer to collaborate on diabetes drug
Pfizer and Merck & Co. are to collaborate on a phase 3 ready diabetes drug ertugliflozin.
Pfizer has already received $60 million in the deal and will earn more when milestones are reached. Merck and Pfizer are sharing profits and some costs on a 60/40 split.
John Young, president and general manager, of primary care, Pfizer said:
“Through this collaboration, we believe we can build on Merck’s leadership position in diabetes care with the introduction of ertugliflozin, an innovative SGLT2 inhibitor discovered by Pfizer scientists.”
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.